SCHEMBL23920263

SCHEMBL23920263

O=C(NC1CCC(NC(=O)C2Cc3ccncc3O2)CC1)C1Cc2cc(Cl)ccc2O1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GLS O94925 3/20 0.51
▸ KMT2A Q03164 2/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ SCN3A Q9NY46 1/20 0.46
▸ CYP1A2 P05177 3/20 0.46
▸ CYP3A4 P08684 3/20 0.46
▸ CYP2C9 P11712 3/20 0.46
▸ CYP2C19 P33261 3/20 0.46
▸ NFKB1 P19838 1/20 0.42
▸ NFKB2 Q00653 1/20 0.42
▸ RELA Q04206 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ C3AR1 Q16581 1/20 0.41
▸ NAMPT P43490 4/20 0.41
▸ ATF4 P18848 1/20 0.40
▸ JAK3 P52333 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ P2RX7 Q99572 1/20 0.38
▸ HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23920621 0.88 KMT2A (0.58) GLSKMT2AMEN1SCN3ACYP1A2
SCHEMBL21050174 0.83 KMT2A (0.54) GLSKMT2AMEN1SCN3ACYP1A2
SCHEMBL23920267 0.83 ATF4 (0.42) GLSCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL24225710 0.82 MEN1 (0.53) GLSKMT2AMEN1SCN3ACYP1A2
SCHEMBL23920219 0.82 CHRNA7 (0.47) KMT2ACYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL23920380 0.81 MAOB (0.41) GLSSCN3ACYP1A2CYP3A4CYP2C9
SCHEMBL23920375 0.81 HRH4 (0.42) CYP1A2CYP3A4CYP2C9CYP2C19NAMPT
SCHEMBL23920262 0.80 HDAC1 (0.38) GLSKMT2AMEN1CYP1A2CYP3A4
SCHEMBL24225718 0.78 GLS (0.48) GLSKMT2AMEN1SCN3ACYP1A2
SCHEMBL28522347 0.78 GLS (0.48) GLSKMT2AMEN1SCN3ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230047589-A1 INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY ALTOS LABS, INC. 2023-02-16 — — US disclosed
US-11230542-B2 Inhibitors of integrated stress response pathway Praxis Biotech LLC (US) 2022-01-25 — — US disclosed
US-20210317102-A1 INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY ALTOS LABS, INC. 2021-10-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317102-A1 INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY ATF4, DDIT3, ATF1 GLS 319/4885KMT2A 4528/4885MEN1 4345/4885
US-11230542-B2 Inhibitors of integrated stress response pathway ATF4, DDIT3, ATF1 GLS 319/4885KMT2A 4528/4885MEN1 4345/4885
US-20230047589-A1 INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY ATF4, DDIT3, ATF1 GLS 319/4885KMT2A 4528/4885MEN1 4345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback